Answers are grounded in this paper and cite their sources.
Given its established clinical use and favorable safety data, nitroxoline emerges as a strong candidate for further investigation as a repurposed treatment for Chagas disease. Future work should focus on in vivo efficacy, pharmacokinetics, and drug delivery strategies to enhance systemic bioavailability.
No takes yet. Share an insight, caveat, or question.
Bethencourt-Estrella et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: